June 7, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) announces that it has entered into an agreement with a German licensed producer applicant, Plantisaneco Gmbh (“Plantisaneco”), whereby Alliance Growers will earn a significant percentage of the equity in Plantisaneco in return for providing certain services and expertise.

No investment is required for the Company to earn its interest in Plantisaneco, and this strategic partnership contemplates securing long term tissue culture plantlet sale contracts for the Company’s Cannabis Botany Centre.

Alliance Growers’ participation has been included in Plantisaneco’s application filed with the Federal Institute for Drugs and Medical Devices in Germany on June 6, 2017.  Approximately 25 to 30 applications were submitted through a tender process whereby each applicant is allowed to apply for up to seven of the ten license contracts being awarded. Successful applicants will be chosen based on the quality of the growers, their experience in the industry, an excellent business plan, and adequate funding to support the implementation of the plan.  Plantisaneco applied for seven of the ten licenses to maximize its chances of success.  They have organized an efficient funding program with a high probability of success through a three stage process beginning with angel investors, followed by well researched grants and ultimately loans from German banking institutions who support this industry.

Alliance Growers is building a Global Cannabis company using a long-term strategy to create a strong company with consistent and growing cash flow with the least amount of regulatory and general business restrictions.  The arrangement with Plantisaneco augments the Company’s stated intent on the development of strategic partnerships with Licensed Producers and Licensed Producer applicants.  Alliance Growers’ and partner growers like Canwe, Plantisaneco and other growers will form business synergies with the goal of creating a strong presence in the fast-growing global medical cannabis space, including the purchase and sale between the parties of live cannabis plants, tissue culture plantlets and other cannabis growers’ products and services.

Commenting on Alliances Growers’ new partnership, Dennis Petke, Alliance Growers’ President and CEO commented, “We have been working diligently to develop significant and valuable strategic partnerships with existing Licensed Growers and Licensed Grower Applicants in connection with the Cannabis Botany Centre. We are exceptionally pleased with the alliance with Plantisaneco as this is our initial “foot in the door” to the European market which is expected to be extremely significant in the years to come.  Alliance is building relationships with the investment community simultaneously through a Class A preferred share offering which is expected to be very well received especially in light of this arrangement. Companies like Plantisaneco are a perfect fit with our long-term strategy for Alliance Growers to become a dominant player in the Cannabis space and successfully build strong shareholder value”.

About Plantisaneco

Plantisaneco is currently a license applicant under the Federal Institute for Drugs and Medical Devices, in the Federal State of Germany.  After the newly passed law for the prescription of medical cannabis and the loosening of the regulations that classified those people that are suffering as eligible, the estimated consumer market will grow rapidly to over 800,000 people within the next few years. To fill the demand, the federal agencies are seeking potential growers who will provide an excellent, high quality product. To benefit from the market opening, Plantisaneco is in the application process to obtain approval for growing licenses of up to 1400 KG of medical cannabis annually.

 About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has executed an agreement with Botanical Research In Motion International Inc., for a Canada Exclusive License to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s corporate website at or the Company’s profile at

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to

On behalf of the board of directors of


“Dennis Petke”

Dennis Petke

President and CEO

For more information contact:

 Dennis Petke

Tel: 778-331-4266

 Rob Grace

Corporate Communications Consultant

Tel: 778-998-5431



This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.